A prospective, phase II clinical trial that used tumor expression of RRM1 and ERCC1 mRNA as detected by real-time quantitative polymerase chain reaction (RT-QPCR) for selection of chemotherapy in advanced NSCLC patients has been recently conducted. This evidence concerns the gene ERCC1 and neoplasm.